유방암 진단 시장 : 제공별, 기술별, 바이오마커 유형별, 검체 유형별, 임상 이용 사례별, 최종 사용자별 시장 예측(2026-2032년)

The Breast Cancer Diagnostics Market is projected to grow by USD 11.54 billion at a CAGR of 8.03% by 2032.

Breast cancer diagnostics is moving from episodic detection toward integrated, risk-based care that combines screening mammography, ultrasound, MRI, biopsy, histopathology, immunohistochemistry, genomic assays, and digital pathology. The clinical urgency is clear: the World Health Organization reported about 2.3 million women diagnosed with breast cancer and roughly 670,000 deaths worldwide in 2022, making timely detection and accurate diagnosis central to cancer control.

For industry leaders, opportunity is tied to earlier detection, faster confirmation, and more precise treatment selection. Demand is strongest where organized screening, reimbursement, pathology capacity, and oncology infrastructure align, making diagnostic accuracy, workflow efficiency, access expansion, and evidence-based care pathways central competitive differentiators.

Transformative Shifts in Breast Cancer Diagnostics

The landscape is being reshaped by three structural shifts: expanded screening access, precision oncology, and digitally enabled diagnostics. Digital breast tomosynthesis is improving lesion visualization, while MRI and ultrasound remain important for dense breast tissue, high-risk patients, and diagnostic follow-up. Updated screening guidance in several countries is also strengthening attention on risk stratification, breast density, and timely diagnostic workup after abnormal findings.

At the same time, biomarker testing for ER, PR, HER2, Ki-67, and multigene recurrence risk has made diagnostics essential to therapy selection. Laboratories and imaging providers are investing in interoperability, quality assurance, standardized reporting, and faster turnaround as health systems prioritize earlier-stage detection, multidisciplinary decision-making, and patient-centered care pathways.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a measurable force in breast imaging and pathology workflows. FDA-listed AI/ML-enabled medical devices are concentrated heavily in radiology, and breast imaging tools are increasingly used for detection support, triage, breast density assessment, image quality review, and quality control. In pathology, AI-assisted image analysis is gaining relevance for digital slide review, workflow prioritization, and reproducibility support.

Evidence is advancing. The MASAI randomized screening trial reported that AI-supported mammography detected more cancers while reducing screen-reading workload, supporting the case for AI as an assistive technology rather than a standalone replacement for radiologists. Adoption will depend on clinical validation, bias monitoring across population groups, cybersecurity, reimbursement, and integration with PACS, RIS, laboratory information systems, and electronic health records.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia increase screening participation, diagnostic imaging capacity, and oncology infrastructure. Growth is supported by rising awareness, expanding private healthcare, and government-led cancer control initiatives, although rural access, affordability, and pathology workforce gaps remain significant in parts of the region. Japan, South Korea, and Australia have mature imaging systems, while China and India continue to scale mammography, ultrasound, biopsy, and pathology services for large populations.

North America leads in advanced mammography, molecular diagnostics, image-guided biopsy, and AI-enabled workflows, supported by reimbursement, clinical guidelines, cancer registries, and strong cancer center networks. Europe benefits from organized screening programs, quality assurance standards, and broad adoption of pathology and biomarker testing across many health systems. Latin America shows rising demand for breast imaging and confirmatory diagnostics, but access remains uneven between urban centers and underserved regions. The Middle East is investing in specialty hospitals, screening campaigns, and imaging networks, whereas Africa faces late-stage presentation, limited mammography density, and pathology bottlenecks that make scalable, cost-effective diagnostics essential.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7 & NATO

ASEAN markets are characterized by rising cancer awareness, expanding urban diagnostic centers, and uneven public screening coverage, creating demand for affordable mammography, ultrasound, biopsy, and pathology services. GCC countries are investing in modern oncology ecosystems, digital hospitals, and national screening initiatives, making premium imaging, integrated diagnostics, and AI-supported workflows increasingly attractive in tertiary care settings.

The European Union benefits from coordinated cancer policy, population-based screening recommendations, conformity assessment standards, and cross-border evidence generation. BRICS markets combine large patient populations with expanding healthcare infrastructure, making access, price-performance, training, and localized service models important for adoption. G7 countries lead in reimbursement depth, guideline-based screening, digital pathology readiness, AI evaluation, and precision diagnostics. NATO member markets add resilience, cybersecurity, data governance, and supply continuity considerations to procurement decisions for critical diagnostic technologies.

Key Country Insights in Breast Cancer Diagnostics

The United States remains a major innovation and adoption hub, with the American Cancer Society estimating more than 310,000 new invasive breast cancer cases in women in 2024 and strong use of mammography, biopsy, pathology, immunohistochemistry, genomic testing, and AI-enabled imaging tools. Canada emphasizes organized screening and equitable provincial access, while Mexico and Brazil show growing demand for diagnostic imaging and pathology services but continue to face regional disparities in screening participation, diagnostic turnaround, and access to specialty oncology care.

The United Kingdom, Germany, France, Italy, and Spain rely on established screening and pathology systems, supported by national or regional breast screening programs, multidisciplinary cancer care, and broad biomarker testing. Russia maintains demand for imaging modernization and oncology infrastructure development. China and India represent scale-driven growth as awareness, hospital investment, and cancer programs expand, while access gaps persist between major cities and lower-resource settings. Japan and South Korea emphasize high-quality imaging, health checkup culture, and technology adoption, and Australia benefits from organized screening, strong clinical governance, and established breast cancer care pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated solutions that shorten the time from abnormal screen to confirmed diagnosis. Investment should focus on interoperable imaging, biopsy guidance, pathology digitization, biomarker testing, and AI tools that demonstrate measurable gains in detection accuracy, workflow efficiency, reproducibility, or patient outcomes.

Commercial strategies must align with local reimbursement, screening policy, regulatory expectations, data governance, and workforce realities. Vendors should build evidence packages for regulators and payers, support training for radiologists, pathologists, technologists, and laboratory teams, and develop tiered offerings for high-income, emerging, and resource-constrained markets without compromising quality assurance or patient safety.

Research Methodology

This research applies a triangulated methodology using verified secondary sources, primary expert inputs, and analytical validation. Core references include WHO, IARC/GLOBOCAN, national cancer registries, CDC, American Cancer Society, USPSTF, FDA device databases, OECD health data, professional society guidelines, and public reimbursement, procurement, and regulatory information.

The research process evaluates epidemiology, screening policy, technology adoption, regulatory pathways, payer dynamics, clinical workflow, competitive positioning, and regional healthcare infrastructure. Findings are cross-checked to avoid unsupported projections and to ensure that market interpretation remains grounded in documented clinical, regulatory, and healthcare system evidence.

Conclusion

Breast cancer diagnostics is entering a new phase defined by earlier detection, precision biomarker testing, digital workflow integration, and responsible AI adoption. The strongest opportunities will emerge where technologies improve diagnostic confidence, reduce delays, and connect imaging with pathology, molecular testing, and treatment planning.

As disease burden remains high worldwide, stakeholders that combine clinical evidence, access strategy, regulatory readiness, data security, and scalable implementation will be best positioned to lead in breast cancer diagnostics while supporting better outcomes across diverse healthcare settings.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Breast Cancer Diagnostics Market, by Offering

• 7.1. Instruments
  • 7.1.1. Biopsy Devices
  • 7.1.2. Imaging Systems
  • 7.1.3. Sequencers
• 7.2. Consumables & Reagents
  • 7.2.1. Assay Kits
  • 7.2.2. Slides & Staining Reagents
• 7.3. Software
  • 7.3.1. Workflow Informatics
  • 7.3.2. Data Analysis Software
• 7.4. Services
  • 7.4.1. Consulting
  • 7.4.2. Installation & Maintenance

8. Breast Cancer Diagnostics Market, by Technology

• 8.1. Biopsy
  • 8.1.1. Needle Biopsy
  • 8.1.2. Surgical Biopsy
• 8.2. Histopathology
  • 8.2.1. Immunohistochemistry
  • 8.2.2. Routine Histology
• 8.3. Imaging
  • 8.3.1. Mammography
  • 8.3.2. Magnetic Resonance Imaging (MRI)
  • 8.3.3. Ultrasound
• 8.4. Molecular Diagnostics
  • 8.4.1. Fluorescence In Situ Hybridization (FISH)
  • 8.4.2. Next-Generation Sequencing (NGS)
  • 8.4.3. PCR-Based

9. Breast Cancer Diagnostics Market, by Biomarker Type

• 9.1. BRCA
• 9.2. ER/PR
• 9.3. HER2
• 9.4. Ki-67

10. Breast Cancer Diagnostics Market, by Sample Type

• 10.1. Blood
• 10.2. Serum
• 10.3. Tissue

11. Breast Cancer Diagnostics Market, by Clinical Use Case

• 11.1. Population Screening
• 11.2. Diagnostic Confirmation
• 11.3. Risk Stratification
• 11.4. Therapy Selection
• 11.5. Treatment Monitoring
• 11.6. Recurrence Surveillance

12. Breast Cancer Diagnostics Market, by End User

• 12.1. Cancer Research Centers
• 12.2. Diagnostic Laboratories
• 12.3. Hospitals & Clinics

13. Breast Cancer Diagnostics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Breast Cancer Diagnostics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Breast Cancer Diagnostics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Hologic, Inc.
• 17.2. F. Hoffmann-La Roche Ltd.
• 17.3. GE HealthCare Technologies Inc.
• 17.4. Siemens Healthineers AG
• 17.5. Thermo Fisher Scientific Inc.
• 17.6. Koninklijke Philips N.V.
• 17.7. FUJIFILM Holdings Corporation
• 17.8. Bio-Rad Laboratories, Inc.
• 17.9. Illumina, Inc.
• 17.10. Danaher Corporation
• 17.11. Abbott Laboratories
• 17.12. Becton, Dickinson and Company
• 17.13. Agilent Technologies, Inc.
• 17.14. Cardinal Health, Inc.
• 17.15. 4D Path Inc.
• 17.16. AstraZeneca PLC
• 17.17. Biodesix, Inc.
• 17.18. Exact Sciences Corporation
• 17.19. Fluxion Biosciences Inc. by Cell Microsystems
• 17.20. NanoString Technologies, Inc.
• 17.21. NeoGenomics Laboratories
• 17.22. Olea Medical
• 17.23. OncoGenomX
• 17.24. Planmed Oy
• 17.25. Quest Diagnostics Incorporated
• 17.26. Todos Medical Ltd.
• 17.27. TransMed7, LLC